

# Orthotopic xenograft model why and how ?

Marc Pocard Inserm U 965 : angiogenesis and translational research Surgical department – Lariboisière Hospital Paris – Université Paris7

Second European Course of in vivo preclinical assays in cancer Therapy



Marc Pocard 2009



# Definition

- Orthotopic : same place as in human
- Xenogaft : cell or tumor fragment
  - Human cell and specific clones
  - Human tumor :


U Inserm 127

- direct surgical or biopsy specimen
- or derived from subcutaneous injection of cells
- Animal cancer cell
- Associated material (radioactive, fluorescent, nano technology, etc.)




Correct for melanoma






# Definition




#### Highly physiological mouse model that closely resembles divers cancer in humans

# Same cells, same animal, same surgical graft procedure



U Inserm 1275



#### Reproducibility Standardization

#### **Statistical analysis**



# For all cancers ?

Liver **Brain** Chest Bone Colon Rectum Prostate Kidney Breast Pancreas Stomach Bladder Skin Ovary

Create a primary tumor

Correlation between any biological specificity (gene function) and a specific tumor behavior

-Tumor growth

- metastasis process







The only solution to obtain tumor growth – because in vitro cell culture failed Rare carcinomatosis : pseudomyxoma


Marc Pocard 2009













#### Osteolytic Bone Metastases (orthotopic injection):










Fifth day following Intrabronchial Implantation with Walker's tumor cells.


Rat presented different tumors location







Colon cancer Caecal graft







	Stage	volume	Volume	IC/S	р
		Scut mm <sup>3</sup>	caecal mm <sup>3</sup>	cut	
TC-10	TxN0M0	343	691	2	0,05
TC-33	TxN0M0	647	2347	3,6	0,008
TC-71	TxN0M0	460	853	1,9	0,015
TC-37	TxN2M0	768	1322	1,7	0,01
TC-7	TxN2M0	569	483	0,85	ns
TC-70	TxN3M0	277	147	0,53	ns
TC-82	TxN3M0	215	256	1,2	ns
TC-118	<b>M</b> 1	715	955	1,3	ns
TC-122	M1	761	679	0,9	ns
LoVo	M1	316	392	1,2	ns


Graft tumor Magneente 2008 or tumor


## Tumor growth regarding divers cells lines



## Local property : tumor and stroma : The stroma came from the murin tissue







Histological aspect of the parental cell line HCT 116

**MSI tumor** 

J Inserm 1275

HCT116 + chr3 after a specific CD34 murin antigen

MSS tumor

Metastatic emboli for a HCT116 + Chr3 MSI stable tumor

Neo vessels


#### ANGIOGENESIS




### Metastasis


- If cells or direct tumors fragment are at the primary sites, did they can create a metastatic process, mimicking the human behavior ?
- Yes but it is inconstant and take time
- Secondary solution : suppress the first part of the metastatic process – direct metastatic sites graft or injection





















#### **Breast cancer**

The 4T1 metastatic breast cancer model is a syngeneic xenograft model based on 4T1-luc12B, a luciferase-expressing clone of the well characterized 4T1 mouse mammary tumor cell line.

Because the model is syngeneic in BALB/c mice, it can be used to study the role of the immune system in tumor growth and metastasis.









#### **General Concept**

Early resection of primary orthotopically-growing human colon tumor in nude mouse prevents liver metastasis: further evidence for patient-like hematogenous metastatic route. Kuo TH, et al. Anticancer Res. 1993 Mar-Apr;13(2):293-7.

**Surgical Concept** 

for the investigation of intraoperative tumor cell spillage during resection of the colon and the development of port site metastases. Balague C, et al. Surg Endosc. 2001 Aug;15(8):833-6.

#### **Treatment Concept**

Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor fr-118487 after removal of growing tumor in mice. Tanaka T, et al. Jpn J Cancer Res. 2001 Jan;92(1):88-94.

# Tumoral graft at day 0, tumor resection at day 30 and results of surgery at day 100

U Inserm 1275 CArcinose Péritoine Paris-Techno

## Metastases


	Nbr animal	No tumor	Lymph nodes	liver	chest
HT-29	4	2/4	2/4	0/4	1/4
LoVo	5	5/5	O/5	O/5	O/5
TC-7	7	0/7	7/7	1/7	1/7
TC-82	4	0/4	2/4	2/4	0/4

# The tumoral genetic property govern the surgical resection result :

Marc Pocard 2009



## P53 - Chromosomique instability




LoVo Caryotype : stability

P53 wild type




### chromosomique

instability induce by muted p53 transfection





#### **FISH** analysisof Lovo Cells lines






# Surgical colon resection at day 15 results at day 45 regarding the p53 status

	LoVo	143 X19	175 X2	273 X17
tumoral	65	87	103	109
volume	±05	±13	±08	±03
% cure	100	100	50	0
local recurrence	0	0	50	100
Lymph nodes	0	0	30	100
Liver	0	0	50	100
Peritoneum	0	0	40	80



#### Inhibition of U87MG gliomablastoma growth by Paclitaxel



•Female Balb/c nu mice were inoculated with 1x106 U87MG cells on D0

- Mice were randomized into two groups (n=10 for each group) when average tumor size reached 100-150 mm<sup>3</sup>
- · Mice were treated with either saline or Paclitaxel via i.p. injection
- Significant inhibition on tumor growth was observed one week days after the first drug treatment (#p<0.05), and the effect maintained throughout the rest of the experiment (\*p<0.01)</li>



## Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer

Punita Dhawan,<sup>1</sup> Amar B. Singh,<sup>2</sup> Natasha G. Deane,<sup>1,3</sup> YiRan No,<sup>1</sup> Sheng-Ru Shiou,<sup>1</sup> Carl Schmidt,<sup>1</sup> John Neff,<sup>1</sup> M. Kay Washington,<sup>4</sup> and R. Daniel Beauchamp<sup>1,5,6</sup>

<sup>1</sup>Surgical Oncology Research Laboratories, Department of Surgery, <sup>2</sup>Department of Medicine, <sup>3</sup>Department of Radiology and Radiological Sciences, <sup>4</sup>Department of Pathology, <sup>5</sup>Department of Cell & Developmental Biology, and <sup>6</sup>Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

The Journal of Clinical Investigation http://www.jci.org Volume 115 Number 7 July 2005



Hypothesis : overexpression of ... is related with metastasis

To asses the impact of overexpression or inhibition of claudin-1 on metastasis in vivo, female athymic/nude mice (7 weeks old; n = 5) were injected in the spleen with 5 · 106 cells of either SW480control and SW480claudin-1 cells or SW620 parental, SW620control, and SW620siRNA cells.

Choosing the right animal model



The spleen was removed after tumor cell injection, and a small hemoclip was applied to the splenic vessels. Nude mice in the SW480 group were sacrificed at 4 weeks, and the number and size of metastatic tumor foci on the surface of the livers were documented.

> Quantification to obtain statistical analysis Marc Pocard 2009

For the SW620 group,

U Inserm 1275

small-animal microPET imaging was used to screen for nonpalpable lesions in the liver, using  $100-150 \propto Ci$  of 18Fdeoxyglucose (18FDG) injected i.p to detect metabolically active foci in the abdomen.


When the tumors were visible by microPET (7 weeks), the mice were subjected to autopsy.

Timing is essential

The number and size of metastatic tumor foci on the surface of the livers were documented.

Always confirm with pathological exam





## Table 2 Effect of overexpression of claudin-1 on liver metastasis

Group	No. of mice with	No. of foci	
	liver metastasis (%)	(mean ± SE)	
SW480 <sup>control</sup>	0/4 (0%)	0	
SW480 <sup>claudin-1</sup> 1	4/4 (100%)	12 ± 0.89 <sup>A</sup>	
SW480 <sup>claudin-1</sup> 2	3/3 (100%)	$10 \pm 0.95$	


AP < 0.05 compared with parental or control.

### Table 3 Effect of inhibition of claudin-1 on liver metastasis


U Inserm 1275


Group	No. of mice with liver metastasis (%)	No.offoci (mean±SE)
SW620	5/5 (100%)	$3.8 \pm 0.71$
SW620 <sup>control</sup>	4/4 (100%)	3.25 ± 0.57
SW620 <sup>sirna</sup> 1	2/4 (50%)	$0.75 \pm 0.48^{A}$
SW620 <sup>sirna</sup> 2	2/4 (50%)	1.25 ± 0.95
SW620sirna3	1/5 (20%) <sup>A</sup>	$0.4 \pm 0.40^{A}$


AP < 0.05 compared with parental or control.




U Inserm 1275 CArcinose Péritoine Paris-Techno



















Н





## Nétrine 4 mutated expression reduce the carcinomatosis in an orthotopic model of human colon cancer carcinomatosis




**LS174** 

FS3






## Mutated Nétrine 4 expression Change the tumor growth



# Bevacizumab did not change the tumoral growth in this model






## limitations

## stem cells – specific interest

### animal right

#### coast

#### uveal melanoma



U Inserm 1275 CArcinose Péritoine Paris-Techno




## Animal experimentation – pain






## experimentation failure









Uveal melanoma : pure hematogenous dissemination One specific metastatic sites



Nobody is perfect






Human uveal melanoma cell line (OCM-1 FRT/Luc) was inoculated Into the anterior chamber of murines eyes or intracardiac injection

4 to 6 weeks : bone – lung – mediastinum No liver metastasis

Marc Pocard 2009



50 days

## **Orthotopic cancer model**

- Orthotopic : Able to mimic any human cancer
- Offer specific possibility
  - Proof of concept regarding : metastasis genetic instability angiogenesis hypothesis
  - Phase 0 study
  - Testing divers therapeutic plan (surgery radio chemo)
- Limitations

- Ethic Coast Material
- Time consuming & can require surgical environment

## Orthotopic cancer model

Nude mice possibility

- Correlation between any genetic abnormality limited to a clone cells versus parental cell line and any specific evolution (volume, chemo sensitivity, surgical or radiotherapy efficiency, metastasis)
- Correlation between any genetic pathway and specific tumor evolution (sub groups identification)
- Immunocompetent mice possibility
  - Testing particular therapeutic algorithm including immune function, or recovery after aggressive treatment
  - Testing particular way of drugs delivery